戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 e benefits and risks of the long-term use of cardiovascular drugs.
2 ting enzyme (ACE) inhibitors are widely used cardiovascular drugs.
3 -years) but no more or less likely to switch cardiovascular drugs.
4 the temporal trends in use of evidence-based cardiovascular drugs.
5 monly used herbs and their interactions with cardiovascular drugs.
6 ge, comorbidities, anticancer therapies, and cardiovascular drugs.
7 osts can impede access to guideline-directed cardiovascular drugs.
8 (2/19), musculoskeletal system drugs (2/19), cardiovascular drugs (1/19), and urogenital and sex horm
9 a, and developed and analyzed an Ontology of Cardiovascular Drug AEs (OCVDAE).
10 iated neuropathy-inducing AEs and OCVDAE for cardiovascular drug AEs, have also been developed and us
11 highlights special considerations related to cardiovascular drugs and devices, emphasizes health equi
12 highlights special considerations related to cardiovascular drugs and devices, emphasizes health equi
13  improve the evidence generation process for cardiovascular drugs and devices.
14 ibes palliative pharmacotherapy inclusive of cardiovascular drugs and essential palliative medicines
15 etics has expanded to study a broad range of cardiovascular drugs and has become a mainstream researc
16 ble responsiveness and toxicity to important cardiovascular drugs and highlight recent developments i
17 n mechanism, and (3) chronotherapies such as cardiovascular drugs and meal timings.
18 lution, and outcomes in the era of effective cardiovascular drugs and widespread use of coronary reva
19 ellow PDDIs was 43% (33% amber - mostly with cardiovascular drugs - and 20% yellow flagged PDDIs) com
20 gin, sex, history of cardiovascular disease, cardiovascular drugs, and cardiovascular risk factors.
21  yellow PDDIs was 43% (33% amber-mostly with cardiovascular drugs-and 20% yellow-flagged PDDIs) compa
22  women as authors of pivotal trials of novel cardiovascular drugs approved by the US Food and Drug Ad
23                                      Several cardiovascular drugs are used for treatment, including c
24 pressant, antineoplastic, antimicrobial, and cardiovascular drugs, as well as oral contraceptive ster
25 e the same therapeutic profile as the parent cardiovascular drug but lacking its metabolic liability
26               During the last years, two new cardiovascular drug classes, namely inhibitors of DPP IV
27                  We focus on 4 commonly used cardiovascular drug classes: aspirin, statins, beta-bloc
28 ene variants that modulate responsiveness to cardiovascular drugs continue to be discovered and valid
29                      With increased usage of cardiovascular drugs (CVDs) for treating cardiovascular
30                              The momentum of cardiovascular drug development has slowed dramatically.
31 den of cardiovascular disease, investment in cardiovascular drug development has stagnated over the p
32 n instrumental in the development of several cardiovascular drug development programs, such as those
33 pies, but biomarkers have been used less for cardiovascular drug development than in therapeutic area
34 ransformative potential of human genetics in cardiovascular drug development, focusing on IL (interle
35 d consensus on improving the environment for cardiovascular drug development, stakeholders from acade
36 s to delineate the current adverse trends in cardiovascular drug development, understand the key issu
37  imaging, have major potential to accelerate cardiovascular drug development, which has been affected
38 serves as a model for the next generation of cardiovascular drug development.
39 research offer promise to greatly facilitate cardiovascular drug development.
40                         We compared rates of cardiovascular drug discontinuation, drug switching, and
41  the coverage gap were at increased risk for cardiovascular drug discontinuation; however, the impact
42 l as effective and innovative H2S donors for cardiovascular drug discovery.
43  $225 000 per year, it is the most expensive cardiovascular drug ever launched in the United States,
44 t differ between users and nonusers of other cardiovascular drugs, except for beta-blockers.
45                  Some cardiovascular and non-cardiovascular drugs frequently cause excessive prolonga
46                                      Certain cardiovascular drugs have adverse effects on glucose hom
47  P-gp substrates and/or inhibitors, and many cardiovascular drugs have recently been observed to have
48                    Of $22.9 billion spent on cardiovascular drugs in Medicare Part D prescription pro
49        Further concerns exist with regard to cardiovascular drug innovation, quality of care, and hea
50                          The pipeline of new cardiovascular drugs is relatively limited compared with
51                   In vivo interaction of the cardiovascular drugs metoprolol (beta-blocker) and ramip
52                   The risk factor potency of cardiovascular drugs on the severity of anaphylaxis in p
53 cations where concentrations of antibiotics, cardiovascular drugs, painkillers, contrast media, and a
54 on of the Medicaid expansion with per-capita cardiovascular drug prescription rates in expander versu
55                                              Cardiovascular drugs show increasing molecular weight wi
56 y and toxicity of other important classes of cardiovascular drugs, such as beta-blockers, is becoming
57 lerotic heart disease, making it a promising cardiovascular drug target.
58  injury, implicating macrophage mPGES-1 as a cardiovascular drug target.
59  Vasopeptidase inhibitors are a new class of cardiovascular drug that simultaneously inhibit both neu
60 wall remodeling can be antagonized by common cardiovascular drugs that act in part by inhibiting vasc
61 w the interactions among commonly prescribed cardiovascular drugs that are P-gp substrates and observ
62 n addition to existing antihyperglycemic and cardiovascular drug therapy.
63 diligent in promoting adherence to guideline cardiovascular drug therapy.
64                The role of therapies such as cardiovascular drugs to prevent and treat complications,
65 nal debate; evidence regarding its impact on cardiovascular drug use and health outcomes is needed.
66                                    Increased cardiovascular drug use and resulting health improvement
67 es, comorbidities, socioeconomic status, and cardiovascular drugs were matched by propensity score me
68 baseline, NYHA class, LV EF, age, and use of cardiovascular drugs were similar between the 2 groups.
69                                              Cardiovascular drugs with narrow therapeutic indexes (e.